<DOC>
	<DOCNO>NCT01819597</DOCNO>
	<brief_summary>Stroke due intracranial arterial atherosclerosis significant medical problem , carry one high rate recurrent stroke despite best medical therapy , annual recurrence rate elevate 25 % high risk group . The goal investigation advance promise surgical treatment symptomatic atherosclerotic intracranial stenosis - encephaloduroarteriosynangiosis ( EDAS ) . The investigation test phase II futility trial potential EDAS development proceed design definitive clinical trial EDAS Revascularization patient Symptomatic Intracranial Arterial Stenosis ( ERSIAS ) . The investigation 4-year futility trial test hypothesis EDAS revascularization combine aggressive medical therapy warrant evaluation subsequent pivotal trial alternative aggressive medical management alone prevent primary endpoint stroke death patient symptomatic intracranial arterial stenosis ( Specific Aim 1 ) . During investigation time course collateralogenesis perfusion improvement follow EDAS also evaluate ( Specific Aim 2 .</brief_summary>
	<brief_title>Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis</brief_title>
	<detailed_description>Intracranial arterial atherosclerosis significant medical problem , elevate rate recurrent stroke despite medical therapy , annual recurrence rate ischemic stroke report SAMMPRIS Trial high 12.2 % intensive medical therapy arm . The incidence recurrence stroke even high high-risk group , high 25 % African-Americans female . The ultimate goal project advance promise surgical treatment symptomatic atherosclerotic intracranial stenosis - encephaloduroarteriosynangiosis ( EDAS ) . Compared direct revascularization operation ( bypass ) , EDAS advantage less technically demand , avoid temporary occlusion cerebral vessel , allow gradual development collateral circulation brain demand , deter early hyperperfusion hemorrhage . There systematic trial explore use EDAS case symptomatic , non-moyamoya intracranial arterial stenosis . Based preliminary positive result , investigator propose long-term objective demonstrating EDAS improve outcome patient symptomatic intracranial stenosis compare aggressive medical therapy . This require future phase III clinical trial . The present proposal purpose test phase II futility-design trial potential EDAS development proceed design definitive clinical trial EDAS Revascularization patient Symptomatic Intracranial Arterial Stenosis ( ERSIAS ) . The present project 4-year futility-design trial determine EDAS revascularization combine aggressive medical therapy warrant evaluation subsequent pivotal trial alternative aggressive medical management alone prevent primary endpoint stroke death two year patient symptomatic intracranial arterial stenosis ( Specific Aim 1 ) . During investigation investigator systematically evaluate time course collateralogenesis perfusion improvement follow EDAS use quantitative semiquantitative perfusion MRI study ( Specific Aim 2 ) . The new knowledge generate study understand role collateral circulation stroke pathophysiology , patient selection , use non-invasive image useful EDAS evaluation potentially next generation stent future novel medical therapy , use angiogenic growth factor and/or endothelial stem cell .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Intracranial Arteriosclerosis</mesh_term>
	<criteria>1 . TIA nonsevere stroke within 30 day enrollment attribute 70 % 99 % stenosis* major intracranial artery ( carotid artery MCA ) *May diagnose TCD , MRA , CTA qualify , must confirm catheter angiography per usual clinical practice . 2 . Modified Rankin scale score ≤3 3 . Target area stenosis intracranial artery normal diameter 2.00 mm 4.50 mm 4 . Target area stenosis ≤14 mm length 5 . Age ≥30 year ≤80 year * Patients 30 49 year age require meet least 1 additional criterion ( ivi ) provide qualify study . This additional requirement increase likelihood symptomatic intracranial stenosis patient 30 49 year atherosclerotic : i. Insulindependent diabetes least 15 year ii . At least 2 follow atherosclerotic risk factor : hypertension ( BP ≥ 140/90 mm Hg antihypertensive therapy ) ; dyslipidemia ( LDL ≥130 mg/dL HDL ≤40 mg/dL fast triglyceride ≥150 mg/dL lipid lower therapy ) ; smoke ; noninsulindependent diabetes insulindependent diabetes &lt; 15 year duration ; family history following : myocardial infarction , coronary artery bypass , coronary angioplasty stenting , stroke , carotid endarterectomy stenting , peripheral vascular surgery parent sibling &lt; 55 year age men &lt; 65 woman time event . iii . History follow : myocardial infarction , coronary artery bypass , coronary angioplasty stenting , carotid endarterectomy stenting , peripheral vascular surgery atherosclerotic disease iv . Any stenosis extracranial carotid vertebral artery , another intracranial artery , subclavian artery , coronary artery , iliac femoral artery , low upper extremity artery , mesenteric artery , renal artery document noninvasive vascular imaging catheter angiography consider atherosclerotic v. Aortic arch atheroma document noninvasive vascular imaging catheter angiography vi . Any aortic aneurysm document noninvasive vascular imaging catheter angiography consider atherosclerotic 6 . Negative pregnancy test female menses last 18 month 7 . Patient willing able return followup visit require protocol . 8 . Patient available phone . 9 . Patient understands purpose requirement study , make him/herself understood , provide informed consent . 10 . Demonstration poor collateral flow territory qualify stenotic vessel ( ASITN/SIR Collateral Flow Grades 02 ) hypoperfusion vascular territory MRI . 1 . Tandem extracranial intracranial stenosis ( 7099 % ) occlusion proximal distal target intracranial lesion 2 . Bilateral intracranial vertebral artery stenosis 70 % 99 % uncertainty artery symptomatic ( e.g. , patient pontine , midbrain , temporal occipital symptom ) 3 . Stenting , angioplasty , endarterectomy extracranial ( carotid vertebral artery ) intracranial artery within 30 day expect enrollment date 4 . Previous treatment target lesion stent , angioplasty , mechanical device , plan perform stag angioplasty follow stenting target lesion 5 . Plan perform concomitant angioplasty stenting extracranial vessel tandem intracranial stenosis 6 . Presence intraluminal thrombus proximal target lesion 7 . Any aneurysm proximal distal stenotic intracranial artery 8 . Intracranial tumor ( include meningioma ) intracranial vascular malformation 9 . Computed tomographic angiographic evidence severe calcification target lesion 10 . Thrombolytic therapy within 24 hour enrollment 11 . Progressive neurologic sign within 24 hour enrollment 12 . Brain infarct within previous 30 day enrollment sufficient size ( &gt; 5 cm ) risk hemorrhagic conversion surgery 13 . Any hemorrhagic infarct within 14 day enrollment 14 . Any hemorrhagic infarct within 15 30 day associate mass effect 15 . Any history primary intracerebral ( parenchymal ) hemorrhage 16 . Any intracranial hemorrhage ( subarachnoid , subdural , epidural ) within 30 day 17 . Any untreated chronic subdural hematoma &gt; 5 mm thickness 18 . Intracranial arterial stenosis relate arterial dissection , MoyaMoya disease ; know vasculitic disease ; herpes zoster , varicella zoster viral vasculopathy ; neurosyphilis ; intracranial infection ; intracranial stenosis associate cerebrospinal fluid pleocytosis ; radiationinduced vasculopathy ; fibromuscular dysplasia ; sickle cell disease ; neurofibromatosis ; benign angiopathy central nervous system ; postpartum angiopathy ; suspect vasospastic process , suspect recanalized embolus 19 . Presence follow unequivocal cardiac source embolism : chronic paroxysmal atrial fibrillation , mitral stenosis , mechanical valve , endocarditis , intracardiac clot vegetation , myocardial infarction within 3 month , dilate cardiomyopathy , leave atrial spontaneous echo contrast , ejection fraction &lt; 30 % 20 . Known allergy contraindication aspirin local general anesthesia 21 . History lifethreatening allergy contrast dye . If lifethreatening effectively pretreated , patient enrol physician 's discretion 22 . Known absolute contraindication obtain MRI study , magnetically activate implanted device ( cardiac pacemaker , insulin pump , neurostimulators , cochlear implant ) , MRI incompatible orthopedic implant , free metallic fragment brain eye . 23 . Active peptic ulcer disease , major systemic hemorrhage within 30 day , active bleeding diathesis , platelet &lt; 100,000 , hematocrit &lt; 30 , INR &gt; 1.5 , clot factor abnormality increase risk bleeding , current alcohol substance abuse , uncontrolled severe hypertension ( systolic BP &gt; 180 mm Hg diastolic BP &gt; 115 mm Hg ) , severe liver impairment ( AST ALT &gt; 3 time normal , cirrhosis ) , creatinine &gt; 3.0 ( unless dialysis ) 24 . Major surgery ( include open femoral , aortic , carotid surgery ) within previous 30 day plan next 90 day enrollment 25 . Indication warfarin heparin beyond enrollment ( NOTE : Exceptions allow use subcutaneous heparin deep venous thrombosis prophylaxis hospitalize ) 26 . Severe neurologic deficit render patient incapable living independently 27 . Dementia psychiatric problem prevents patient follow outpatient program reliably 28 . Comorbid condition may limit survival &lt; 3 year 29 . Females pregnant childbearing potential unwilling use contraception duration study 30 . Enrollment another study would conflict current study Surgical Specific In addition enumerate , give surgical nature intervention patient fail best medical therapy , follow additional exclusion criterion : 1 . Use clopidogrel extended release dipyridamole within 7 day date surgery . This exclusion base elevate risk hemorrhagic complication intracranial surgery use agent accord current AHA/ACC Guidelines ( Fleisher et al. , 2007 ) . 2 . Evidence active , untreated focal systemic infection ( i.e . pneumonia , urinary tract infection , skin abscess ) history recurrent infection despite treatment last 6 month . 3 . Coagulation disorder characterize PTT ≥ 34 , PT ≥ 12 , INR ≥ 1.3 , platelet count &lt; 80,000 . 4 . Noncontrolled hyperglycemia ( preprandial glucose level ≥ 180 mg/dL single test within 30 day enrollment ) hemoglobin A1c ( HbA1c ) ≥7 % . 5 . A lowdensity lipoprotein cholesterol ( LDLc ) ≥ 130 mg/dL . 6 . A nonhighdensity lipoprotein cholesterol ( nonHDLc ) ≥ 100 mg/dL . 7 . Smoking history last 6 month . 8 . BMI ≥ 30 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Intracranial Arterial Stenosis</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Stroke</keyword>
	<keyword>EDAS</keyword>
	<keyword>Angiogenesis</keyword>
</DOC>